Beneficial Combination of Lacosamide with Retigabine in Experimental Animals: An Isobolographic Analysis

Conclusion: LCM combined with retigabine possesses a beneficial preclinical profile (benefit index ranged from 2.07 to 2.50) and this 2-drug combination is worth recommending as treatment plan to patients with pharmacoresistant epilepsy.Pharmacology 2018;101:22-28
Source: Pharmacology - Category: Drugs & Pharmacology Source Type: research